Evidence map›Paper›PMID 41759530›Full record

ArticleCell reports. Medicine2026

Phylogenomics-driven metalloantibiotic engineering: Overcoming ciprofloxacin resistance in Pseudomonasaeruginosa with sideromycin-bismuth synergy.

Jianwei Chen, Jiangwei Pan, Xingyue Lu, Lu Wang, Keli Tan, Yujie Yue, Liting Gu, Siqi Wang, Minghong Chen, Hong Jiang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jianwei ChenCollege of Pharmaceutical Science & Jianxing Honors College, Zhejiang University of Technology, Hangzhou 310014, China. Electronic address: cjw983617@zjut.edu.cn.
Jiangwei PanCollege of Pharmaceutical Science & Jianxing Honors College, Zhejiang University of Technology, Hangzhou 310014, China.
Xingyue LuCollege of Pharmaceutical Science & Jianxing Honors College, Zhejiang University of Technology, Hangzhou 310014, China.
Lu WangCollege of Pharmaceutical Science & Jianxing Honors College, Zhejiang University of Technology, Hangzhou 310014, China.
Keli TanCollege of Pharmaceutical Science & Jianxing Honors College, Zhejiang University of Technology, Hangzhou 310014, China.
Yujie YueCollege of Pharmaceutical Science & Jianxing Honors College, Zhejiang University of Technology, Hangzhou 310014, China.
Liting GuCollege of Pharmaceutical Science & Jianxing Honors College, Zhejiang University of Technology, Hangzhou 310014, China.
Siqi WangCollege of Pharmaceutical Science & Jianxing Honors College, Zhejiang University of Technology, Hangzhou 310014, China.
Minghong ChenFujian Provincial Key Laboratory of Screening for Novel Microbial Products, Fujian Institute of Microbiology, Fuzhou 350007, China.
Hong JiangFujian Provincial Key Laboratory of Screening for Novel Microbial Products, Fujian Institute of Microbiology, Fuzhou 350007, China.
Yu PanInstitute of Microbiology, Heilongjiang Academy of Sciences, Harbin 150010, Heilongjiang, China.
Yuanquan YuThe Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Jianwei NaiCollege of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou 310014, China.
Dahong ZhangUrology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
Hong WangCollege of Pharmaceutical Science & Jianxing Honors College, Zhejiang University of Technology, Hangzhou 310014, China. Electronic address: hongw@zjut.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance exacerbates the difficulty of clinical bacterial infection treatment, as single-target antibiotics rapidly lose efficacy shortly post-clinical use. Such resistance highlights an urgent need for multitargeted therapeutics. Metalloantibiotics, combining metal ions with antimicrobials to disrupt diverse bacterial pathways, represent a promising strategy to circumvent resistance. Here, we engineer a sideromycin-bismuth molecular nanoassembly for treating ciprofloxacin-resistant Pseudomonas aeruginosa. Using phylogenomics-driven methods, we identify four hydroxamate siderophores from Streptomyces fradiae and rationally design sideromycin 7 by a structure-based strategy. Sideromycin 7 forms a 7-Bi

Indexed as

Anti-Bacterial AgentsCiprofloxacinDrug Resistance, BacterialPeptidesPseudomonas aeruginosaAnimalsDrug SynergismFerrous CompoundsMiceMicrobial Sensitivity TestsPhylogenySiderophoresStreptomycesAnti-Bacterial AgentsCiprofloxacinFerrous CompoundsPeptidessideromycinsSiderophoresmetalloantibioticP. aeruginosasideromycinsiderophore

Identifiers

PMID41759530
PMCPMC13006412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.